Abstract

A male infant affected by type 0 SMA with one copy of SMN2 received early treatment with Nusinersen at the age of 13 days. He showed mild motor improvement 2 months after treatment started but despite also showing some minimal respiratory improvement, required tracheostomy at the age of 4 months and had increasing cardiac and autonomic dysfunction leading to exitus at 5 months. Our findings, expanding the results available on Nusinersen, confirm its relative efficacy in the most severely affected infants and provide clinical evidence to be used at the time requests for treating severe infants are discussed.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalAnnals of Clinical and Translational Neurology
DOIs
Publication statusPublished - 2020

Keywords

  • type 0 spinal muscular atrophy

Fingerprint

Dive into the research topics of 'Nusinersen in type 0 spinal muscular atrophy: should we treat?'. Together they form a unique fingerprint.

Cite this